BRPI1006443A2 - proteína ou peptídeo de fusão de meia-vida aumentada in vivo mantidos por liberação sustentada in vivo, e método para aumentar a meia-vida in vivo usando os mesmos. - Google Patents

proteína ou peptídeo de fusão de meia-vida aumentada in vivo mantidos por liberação sustentada in vivo, e método para aumentar a meia-vida in vivo usando os mesmos.

Info

Publication number
BRPI1006443A2
BRPI1006443A2 BRPI1006443A BRPI1006443A BRPI1006443A2 BR PI1006443 A2 BRPI1006443 A2 BR PI1006443A2 BR PI1006443 A BRPI1006443 A BR PI1006443A BR PI1006443 A BRPI1006443 A BR PI1006443A BR PI1006443 A2 BRPI1006443 A2 BR PI1006443A2
Authority
BR
Brazil
Prior art keywords
life
vivo
vivo half
increasing
increased
Prior art date
Application number
BRPI1006443A
Other languages
English (en)
Inventor
Hye-Shin Chung
Sang Mee Lee
Seung Bum Yoo
Original Assignee
Alteogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alteogen Inc filed Critical Alteogen Inc
Publication of BRPI1006443A2 publication Critical patent/BRPI1006443A2/pt
Publication of BRPI1006443B1 publication Critical patent/BRPI1006443B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BRPI1006443-5A 2009-04-22 2010-04-22 Proteína ou peptídeo de fusão e método para aumentar a meia-vida in vivo de uma proteína ou peptídeo BRPI1006443B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20090035190 2009-04-22
KR10-2009-0035190 2009-04-22
PCT/KR2010/002520 WO2010123290A2 (ko) 2009-04-22 2010-04-22 체내 지속성을 유지함으로 체내 반감기가 증가된 단백질 또는 펩티드 융합체, 및 이를 이용하여 체내 반감기를 증가시키는 방법

Publications (2)

Publication Number Publication Date
BRPI1006443A2 true BRPI1006443A2 (pt) 2016-09-27
BRPI1006443B1 BRPI1006443B1 (pt) 2021-05-25

Family

ID=43011621

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1006443-5A BRPI1006443B1 (pt) 2009-04-22 2010-04-22 Proteína ou peptídeo de fusão e método para aumentar a meia-vida in vivo de uma proteína ou peptídeo

Country Status (11)

Country Link
US (1) US9012606B2 (pt)
EP (1) EP2423233B1 (pt)
JP (1) JP5727459B2 (pt)
KR (1) KR101183262B1 (pt)
CN (1) CN102439044B (pt)
AU (1) AU2010239861B2 (pt)
BR (1) BRPI1006443B1 (pt)
CA (1) CA2758445C (pt)
MX (1) MX2011011130A (pt)
RU (1) RU2503688C2 (pt)
WO (1) WO2010123290A2 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012178102A2 (en) 2011-06-24 2012-12-27 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
KR102231139B1 (ko) * 2011-06-28 2021-03-24 인히브릭스, 인크. 세르핀 융합 폴리펩타이드 및 이의 이용 방법
KR101402702B1 (ko) * 2011-09-15 2014-06-05 (주)알테오젠 신규한 알파-1 안티트립신 변이체, 이의 제조방법 및 용도
CA2896951A1 (en) 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
AU2013263349B2 (en) 2012-05-17 2016-09-08 Extend Biosciences, Inc Carriers for improved drug delivery
US9902753B2 (en) 2012-06-05 2018-02-27 Cj Healthcare Corporation Method of purifying a long-acting human growth hormone
KR101460266B1 (ko) * 2012-06-05 2014-11-11 씨제이헬스케어 주식회사 신규한 지속형 인간 성장호르몬의 정제 방법
KR101504824B1 (ko) * 2013-05-31 2015-03-23 씨제이헬스케어 주식회사 고당화된 지속형 인간 성장호르몬 단백질 및 이의 제조방법
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
KR101516054B1 (ko) * 2012-11-21 2015-05-06 씨제이헬스케어 주식회사 신규한 지속형 인간 성장호르몬 단량체를 제조하는 방법
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
GB201322091D0 (en) * 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US20170334971A1 (en) * 2014-12-22 2017-11-23 Novo Nordisk A/S Alpha-1-Antitrypsin (A1AT) Fusion Proteins and Uses Thereof
CN106397606B (zh) * 2015-01-28 2020-11-10 中国科学院天津工业生物技术研究所 一种多肽复合物作为sst药物载体的应用、方法及其融合蛋白复合物
US10993993B2 (en) * 2015-05-28 2021-05-04 Immunoforge Co., Ltd. Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2017003270A1 (ko) * 2015-07-02 2017-01-05 주식회사 녹십자 헌터증후군 치료제 및 치료방법
KR20170004814A (ko) 2015-07-02 2017-01-11 주식회사 녹십자 헌터증후군 치료제
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CA3183289A1 (en) * 2015-09-08 2017-03-16 Jcr Pharmaceuticals Co., Ltd. Novel human serum albumin mutant
WO2018071528A1 (en) * 2016-10-11 2018-04-19 University Of Georgia Research Foundation, Inc. Proteins and method for treating obesity and associated comorbidities
US11492390B2 (en) * 2017-04-02 2022-11-08 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Mutant alpha-1-antitrypsin compositions and use thereof
KR101964376B1 (ko) 2017-09-29 2019-04-01 주식회사 나이벡 부갑상선호르몬(parathyroid hormone, PTH)에 골조직 선택성 펩타이드가 결합되어 있는 융합 펩타이드를 포함하는 약학 조성물 및 생체재료
KR102167827B1 (ko) * 2017-12-20 2020-10-20 주식회사 알테오젠 신규한 성장 호르몬 수용체 길항제 및 이의 융합 단백질
CN107916257B (zh) * 2018-01-09 2020-07-28 华南理工大学 T1脂肪酶突变体和应用
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
CN112839964A (zh) * 2018-06-07 2021-05-25 普泰公司 包含融合蛋白的药物组合物及其用途
EP3848388B1 (en) 2018-09-05 2025-08-20 LG Chem, Ltd. Fusion polypeptide comprising polypeptide region that can be o-glycosylated
CA3117961A1 (en) 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders
CN114573715A (zh) * 2022-03-14 2022-06-03 江苏雅酶医药科技有限公司 一种重组长效人透明质酸酶及其生产方法和应用
CN117186237A (zh) * 2022-05-29 2023-12-08 中国医学科学院药物研究所 一种含有糜蛋白酶抑制肽的胰岛素杂交肽及其应用
KR20250075704A (ko) 2022-09-30 2025-05-28 익스텐드 바이오사이언시즈, 인크. 장기-지속형 부갑상선 호르몬

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601033B1 (fr) * 1986-07-02 1990-01-19 Transgene Sa Variants de l'alpha-antitryspine humaine glycosylee et procede pour la preparation
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US7217689B1 (en) 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
KR100239336B1 (ko) 1992-09-29 2000-01-15 구본준 액정 표시 소자
CA2150803C (en) 1992-12-02 2006-01-31 Henry Auer Controlled release growth hormone containing microspheres
KR100236771B1 (ko) 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
US7247704B2 (en) * 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
EP2287326A1 (en) * 2003-08-08 2011-02-23 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
ES2383300T3 (es) * 2003-11-13 2012-06-20 Hanmi Holdings Co., Ltd Fragmento Fc de IgG para un vehículo de fármacos y procedimiento para su preparación
TW200607523A (en) 2004-06-01 2006-03-01 Domantis Ltd Drug compositions, fusions and conjugates
US8658174B2 (en) 2005-07-27 2014-02-25 Qinghua Wang GLP/1/exendin 4 IgG Fc fusion constructs for treatment of diabetes

Also Published As

Publication number Publication date
US20120094356A1 (en) 2012-04-19
EP2423233A2 (en) 2012-02-29
WO2010123290A2 (ko) 2010-10-28
WO2010123290A3 (ko) 2011-03-03
RU2503688C2 (ru) 2014-01-10
BRPI1006443B1 (pt) 2021-05-25
KR20100116558A (ko) 2010-11-01
AU2010239861A1 (en) 2011-10-27
CN102439044B (zh) 2014-08-13
KR101183262B1 (ko) 2012-09-14
JP2012524062A (ja) 2012-10-11
JP5727459B2 (ja) 2015-06-03
EP2423233B1 (en) 2015-03-11
EP2423233A4 (en) 2012-09-26
CA2758445C (en) 2016-02-16
RU2011147216A (ru) 2013-05-27
US9012606B2 (en) 2015-04-21
AU2010239861B2 (en) 2013-07-11
MX2011011130A (es) 2011-11-18
CA2758445A1 (en) 2010-10-28
CN102439044A (zh) 2012-05-02

Similar Documents

Publication Publication Date Title
BRPI1006443A2 (pt) proteína ou peptídeo de fusão de meia-vida aumentada in vivo mantidos por liberação sustentada in vivo, e método para aumentar a meia-vida in vivo usando os mesmos.
LTC2358756I2 (lt) Žmogaus antikūnai, pasižymintys dideliu giminingumu pcsk9
BRPI0918947A2 (pt) proteína de fusão de anticorpo
ATE524493T1 (de) Exendin-fusionsproteine
BRPI0817294A2 (pt) Método de modificação do ponto isoelétrico de anticorpo via substituição de aminoácido em cdr.
BRPI0819714A2 (pt) Formulações de proteína e métodos de produção das mesmas.
BRPI1008971A2 (pt) métodos para preparar uma proteína biológica condicionalmente ativa, e um modificador de resposta biológica condicionalmente ativo, proteína biológica condicionalmente ativa, e, composição farmacêutica
BR112012003663A2 (pt) demarcações de pavimentos, elementos refletivos, e métodos de preparo de microesferas.
DK2307543T3 (da) Forbedret proteinekspressionssystem
BRPI1011592A2 (pt) "composição, e, método para fazer manutenção em um furo de poço."
BR112013028892A2 (pt) proteína de ligação à biotina modificada, proteínas de fusão da mesma e aplicações
BRPI0923159A2 (pt) gene de delta-endotoxina axmi-150 e métodos para sua utilização.
BR112012000281A2 (pt) proteína quimérica.
PL2144924T3 (pl) Szczepionka z białkiem fuzyjnym
BR112012002711A2 (pt) metodo para avaliar o estado renal em um individuo, e, medicao de proteina
EP2475771A4 (en) NEW PROLIPASE BOVINE TRYPSINOGENFUSION PROTEINS
WO2010014922A3 (en) Protein purification tags and uses thereof
BRPI1011531A2 (pt) composto, e , método para fluoração de 18f.
IL232867B (en) Amyloid-binding polypeptide and chimeric protein containing it, pharmaceutical preparations containing the polypeptide or chimeric protein, methods for their preparation and uses
BRPI0814576A2 (pt) Item de calçado, e, métodos para preparar um item de calçado, e para aperfeiçoar o conforto de um item de calçado para o usuário.
BRPI0823029A2 (pt) Conjunto, e, método para fazer um conjunto.
BR112012009569A2 (pt) componente de articulação com pino, método para formar um componente de articulação com pino e conjunto de articulação com pino
BRPI0924214A2 (pt) proteínas de fusão, processo para a sua preparação e sua utilização em sistemas de expressão de proteínas recombinantes.
FR2946244B1 (fr) Sonde pour insemination artificielle, notamment de porcins.
JP2012532903A5 (pt)

Legal Events

Date Code Title Description
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/04/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF